• Sep 18, 2025

    Newsroom

    Material Information - Announcement on Behalf of PharmaEssentia Japan KK: Filing for an Additional Indication of BESREMi (Ropeginterferon alfa-2b) for ET in Japan

    Learn More

  • Sep 11, 2025

    Newsroom

    Material Information - The Health Canada has Accepted the New Drug Submission of Ropeginterferon alfa-2b for PV

    Learn More

  • Sep 5, 2025

    Newsroom

    PharmaEssentia August 2025 Revenue Report

    Learn More

  • Sep 5, 2025

    Newsroom

    Material Information - PharmaEssentia Files for an Additional Indication of Besremi (Ropeginterferon alfa-2b) for the Treatment of Essential Thrombocythemia (ET) with TFDA

    Learn More

  • Aug 19, 2025

    Newsroom

    PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference

    Learn More

  • Aug 5, 2025

    Newsroom

    PharmaEssentia July 2025 Revenue Report

    Learn More

  • Jul 18, 2025

    Newsroom

    Material Information - The Company Announces Filing of New Drug Submission of BESREMi (Ropeginterferon alfa-2b) for PV in Canada

    Learn More

  • Jul 16, 2025

    Newsroom

    Material Information - The China NMPA has Accepted the Marketing Authorization Application of Ropeginterferon alfa-2b for ET

    Learn More

  • Jul 5, 2025

    Newsroom

    PharmaEssentia June 2025 Revenue Report

    Learn More

  • Jun 30, 2025

    Newsroom

    Material Information - The Company Announces Submission of Marketing Authorization Application of Ropeginterferon alfa-2b (P1101) for ET in China

    Learn More

  • Jun 18, 2025

    Newsroom

    Material Information - Argentina ANMAT has Approved the Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2b) for PV

    Learn More

  • Jun 12, 2025

    Newsroom

    Material Information - Update on the Company's IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors

    Learn More

  • Jun 6, 2025

    Newsroom

    PharmaEssentia May 2025 Revenue Report

    Learn More

  • Jun 4, 2025

    Newsroom

    PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms

    Learn More

  • May 24, 2025

    Newsroom

    Material Information - Announcement of the Topline Results from the Phase I Clinical Trial of PharmaEssentia's Long-acting GCSF, P2203

    Learn More
/3